{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:33:43Z","timestamp":1786545223804,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ACG Case Rep J","ACG Case Reports Journal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vedolizumab is a monoclonal antibody against the \u02514\u03b27 integrin receptor used for the treatment of ulcerative colitis and Crohn's disease. Clinical trials have shown vedolizumab to be a safe and highly effective therapy in treating inflammatory bowel disease. Its unique gut-specific mechanism of action has made it an attractive agent in recent years. However, vedolizumab's side effect profile and long-term effects are not fully understood. We report a patient with ulcerative colitis who presented with epistaxis 1 week after receiving the first induction dose of vedolizumab found to have a severe immune-mediated thrombocytopenia and hemolytic anemia, otherwise known as Evan's syndrome.<\/jats:p>","DOI":"10.14309\/crj.0000000000000002","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T01:00:44Z","timestamp":1550106044000},"page":"e00002","source":"Crossref","is-referenced-by-count":5,"title":["A Case of Evan's Syndrome Induced by Vedolizumab"],"prefix":"10.14309","volume":"6","author":[{"given":"Henry","family":"Jen","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Stony Brook University Hospital, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Morganstern","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Stony Brook University Hospital, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"D'Souza","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Stony Brook University Hospital, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"key":"R1-20230717","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastro Hep"},{"key":"R2-20230717","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"R3-20230717","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archinte.1951.03810010058005","article-title":"Primary thrombocytopenic purpura and acquired hemolytic anemia","volume":"87","author":"Evans","year":"1951","journal-title":"Arch Intern Med"},{"issue":"4","key":"R4-20230717","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.2830150409","article-title":"Immunoregulatory abnormalities in Evans syndrome","volume":"15","author":"Wang","year":"1983","journal-title":"Am J Hematol"},{"issue":"6","key":"R5-20230717","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2004-09-3542","article-title":"Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome","volume":"105","author":"Teachey","year":"2005","journal-title":"Blood"},{"key":"R6-20230717","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217246","article-title":"Example of the drug interaction between ciclosporin and orlistat, resulting in relapse of Evans syndrome","author":"Earnshaw","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"12","key":"R7-20230717","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bmt.1701017","article-title":"Evans syndrome after autologous bone marrow transplant for recurrent Hodgkin's disease","volume":"20","author":"Keung","year":"1997","journal-title":"Bone Marrow Transpl"},{"key":"R8-20230717","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.2005.05809.x","article-title":"Management of Evans syndrome","volume":"132","author":"Norton","year":"2005","journal-title":"Br J Hematol"}],"container-title":["ACG Case Reports Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02075970-201901000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:38:18Z","timestamp":1786541898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02075970-201901000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.14309\/crj.0000000000000002","relation":{},"ISSN":["2326-3253"],"issn-type":[{"value":"2326-3253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}